{"product_id":"tamoxifen-inducible-cre-creert2-rfp-adenovirus-ad-rfp-creert2-bhv21600365","title":"Tamoxifen inducible Cre (CreERT2-RFP) Adenovirus (Ad-RFP-CreERT2)","description":"\u003ch2\u003eOverview\u003c\/h2\u003e\u003cp\u003eAd-RFP-CreERT2 is a replication-defective recombinant Ad5 adenovirus expressing tamoxifen-inducible the RFP-CreERT2 recombinase under the CMV promoter. It is used to deliver Cre activity to floxed alleles in cell lines and in vivo for conditional gene knockout, lineage tracing, and activation of Cre-dependent (DIO\/FLEX) reporters.\u003c\/p\u003e\u003ch2\u003eKey elements and design rationale\u003c\/h2\u003e\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003eBackbone:\u003c\/strong\u003e Human adenovirus type 5 (Ad5) with E1 and E3 deleted (dE1\/E3). Replication-incompetent in standard cells; replication-competent helper cells (HEK293) are required for amplification.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003ePromoter (CMV):\u003c\/strong\u003e a strong, ubiquitous promoter active in most mammalian cell types.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eTransgene:\u003c\/strong\u003e RFP-CreERT2.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eTiter \u0026amp; format:\u003c\/strong\u003e 1×10\u003csup\u003e10\u003c\/sup\u003e PFU\/ml in storage buffer (DMEM, 2% BSA, 2.5% glycerol or equivalent), supplied as a 200 µL aliquot.\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch2\u003eBiological background\u003c\/h2\u003e\u003cp\u003eA mutated form of estrogen ligand-binding domain (ERT2) that binds to synthetic antagonists (such as tamoxifen or its derivative 4-hydroxy-tamoxifen) but not to circulating estrogens was fused to the Cre recombinase (Cre) to create the CreERT2, which requires the presence of tamoxifen for Cre recombinase activity. Therefore it makes possible to induce the recombination in cells with tamoxifen.\u003c\/p\u003e\u003cp\u003eThis adenovirus expresses both CreERT2 and RFP under the same CMV promoter, and the 2 genes are separated by a 2A polypeptide.\u003c\/p\u003e\u003ch2\u003eResearch relevance and current trends\u003c\/h2\u003e\u003cul\u003e\n\u003cli\u003eDecision-relevant for researchers studying Recombinases.\u003c\/li\u003e\n\u003cli\u003eAdenovirus-mediated delivery is well-established in primary cells, organoids, and small-animal models.\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch2\u003eCommon research applications\u003c\/h2\u003e\u003cul\u003e\n\u003cli\u003eTamoxifen-controlled conditional gene knockout for temporal precision.\u003c\/li\u003e\n\u003cli\u003eInducible lineage tracing in adult tissues.\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch2\u003eNotes for experimental interpretation\u003c\/h2\u003e\u003cul\u003e\n\u003cli\u003eRecombination efficiency depends on Cre expression level, allele accessibility, and the time window assayed; allow 72–96 hours after infection for recombination to plateau.\u003c\/li\u003e\n\u003cli\u003eAdenoviral delivery is episomal and non-integrating; expression dilutes with cell division and typically lasts 1–2 weeks in dividing cells (longer in non-dividing cells such as hepatocytes, neurons, and cardiomyocytes).\u003c\/li\u003e\n\u003cli\u003ePre-existing anti-Ad5 neutralizing antibodies are common in human and primate hosts and can reduce in vivo transduction; this is less relevant in inbred laboratory mouse strains.\u003c\/li\u003e\n\u003cli\u003eMOI optimization is essential — over-dosing can cause cytopathic effects; under-dosing yields incomplete transduction. A 3–5× MOI titration in your specific cell or animal model is recommended.\u003c\/li\u003e\n\u003cli\u003eReplication-defective Ad5 vectors are typically handled at BSL-2; consult your institutional biosafety officer for specific transgenes and routes of use.\u003c\/li\u003e\n\u003c\/ul\u003e\u003c!-- Sources (internal):\n  - NCBI Gene: https:\/\/www.ncbi.nlm.nih.gov\/gene\n  - UniProt: https:\/\/www.uniprot.org\/\n  - Russell WC. Adenoviruses: update on structure and function. J Gen Virol 2009; 90:1–20.\n  - Alba R, Bosch A, Chillon M. Gutless adenovirus: last-generation adenovirus for gene therapy. Gene Ther 2005; 12 Suppl 1:S18–27.\n  - Sauer B, Henderson N. Site-specific DNA recombination in mammalian cells by the Cre recombinase of bacteriophage P1. Proc Natl Acad Sci USA 1988; 85:5166–70.\n  - Indra AK et al. Temporally-controlled site-specific mutagenesis in the basal layer of the epidermis. Nucleic Acids Res 1999; 27:4324–7.\n  - Vendor reference: https:\/\/www.vectorbiolabs.com\/product\/1797-tamoxifen-inducible-cre-creert2-rfp-adenovirus\/\n--\u003e","brand":"Vector Biolabs","offers":[{"title":"1x10^10 PFU\/ml \/ 200 µL","offer_id":53286500761965,"sku":"1797","price":495.0,"currency_code":"USD","in_stock":true}],"url":"https:\/\/www.ebiohippo.com\/products\/tamoxifen-inducible-cre-creert2-rfp-adenovirus-ad-rfp-creert2-bhv21600365","provider":"BioHippo","version":"1.0","type":"link"}